AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2564834 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 71
Study 2564834 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 97474 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly interviews
Number of subjects: 691
Study 97474 — intervention group
Group type: COMPARATOR
Intervention: Bimonthly interviews
Number of subjects: 691
Study 97474 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person contact
Number of subjects: 691
Study 97474 — intervention group
Group type: COMPARATOR
Intervention: Telephone contact
Number of subjects: 691
Study 31823379 — intervention group
Group type: EXPERIMENTAL
Intervention: Triad intervention with an additional TD peer added to the existing dyad, delivered over four clinic sessions by a trained occupational therapist.
Number of subjects: 15
Study 31823379 — intervention group
Group type: EXPERIMENTAL
Intervention: Triad intervention with an additional TD peer added to the existing dyad.
Number of subjects: 15
Study 31823379 — intervention group
Group type: COMPARATOR
Intervention: Dyad intervention as part of a randomised control trial investigation of the PLF.
Number of subjects: 15
Study 31106851 — intervention group
Group type: EXPERIMENTAL
Intervention: DIFFMASK score (0 to 18 points)
Number of subjects: 46804
Study 27838195 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial image displays (Electronic Whiteboard - EWB) added to textual histories
Number of subjects: 0
Study 27838195 — intervention group
Group type: COMPARATOR
Intervention: Textual information alone
Number of subjects: 0
Study 27838195 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial image displays (EWB)
Number of subjects: 0
Study 24990176 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and behavioral intervention (EBI)
Number of subjects: 25
Study 24990176 — intervention group
Group type: COMPARATOR
Intervention: Attention control (AC)
Number of subjects: 25
Study 23444007 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry-sponsored gifts
Number of subjects: 2350
Study 23444007 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals outside the hospital
Number of subjects: 2350
Study 23444007 — intervention group
Group type: EXPERIMENTAL
Intervention: Free drug samples
Number of subjects: 2350
Study 23444007 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of bias from industry interactions
Number of subjects: 2350
Study 23444007 — intervention group
Group type: COMPARATOR
Intervention: NIH funding levels
Number of subjects: 2350
Study 23444007 — intervention group
Group type: COMPARATOR
Intervention: Strength of institutional conflict of interest policies
Number of subjects: 2350
Study 21291440 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting-focused preventive intervention
Number of subjects: 240
Study 19267194 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 195
Study 16778712 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg/d for 11 days
Number of subjects: 12
Study 16778712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16778712 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 12
Study 16778712 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg single oral dose)
Number of subjects: 12
Study 15513547 — intervention group
Group type: EXPERIMENTAL
Intervention: VR implantation
Number of subjects: 39
Study 15513547 — intervention group
Group type: COMPARATOR
Intervention: Real surgery
Number of subjects: 39
Study 10675059 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic gas mixture (inspired oxygen fraction = 40%)
Number of subjects: 17
Study 10675059 — intervention group
Group type: COMPARATOR
Intervention: Normoxic gas mixture
Number of subjects: 17
Study 9264477 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week physical training
Number of subjects: 140
Study 12959287 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet (155 mg rac‐hydroxychloroquine)
Number of subjects: 9
Study 12959287 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution (155 mg rac‐hydroxychloroquine)
Number of subjects: 9
Study 12959287 — intervention group
Group type: COMPARATOR
Intervention: Fasted subjects (previously reported)
Number of subjects: 9
Study 3040923 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy (CAV and VP-16/cisplatin for six cycles)
Number of subjects: 300
Study 3040923 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy (three cycles of CAV followed by three of VP-16/cisplatin)
Number of subjects: 300
Study 3040923 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy
Number of subjects: 300
Study 3040923 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 300
Study 30566245 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective sigmoid resection
Number of subjects: 106
Study 30566245 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 106
Study 29463769 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (facilitated, group‐based educational discussion on mindful hand hygiene)
Number of subjects: 4
Study 29463769 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mindfulness intervention)
Number of subjects: 4
Study 26525188 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Number of subjects: 80
Study 26525188 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 25298043 — intervention group
Group type: EXPERIMENTAL
Intervention: Information regarding the trial; Enrollment process; Community involvement; Explanation of trial procedures and risks/benefits
Number of subjects: 300
Study 22500385 — intervention group
Group type: EXPERIMENTAL
Intervention: Jinhuang Yidan Granule (JYD)
Number of subjects: 66
Study 22500385 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Chinese medicine)
Number of subjects: 66
Study 20602004 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately painful intracutaneous electrical stimuli
Number of subjects: 36
Study 20602004 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 36
Study 17591031 — intervention group
Group type: COMPARATOR
Intervention: d4T40 arm (stavudine 40 mg twice daily)
Number of subjects: 58
Study 17591031 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T30 arm (stavudine 30 mg twice daily)
Number of subjects: 58
Study 17591031 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF arm (switch to tenofovir)
Number of subjects: 58
Study 17591031 — intervention group
Group type: COMPARATOR
Intervention: d4T40 arm
Number of subjects: 58
Study 17591031 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T30 arm
Number of subjects: 58
Study 17591031 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF arm
Number of subjects: 58
Study 17591031 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 58
Study 15546225 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling
Number of subjects: 271
Study 15546225 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education
Number of subjects: 271
Study 11503006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 30
Study 11503006 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 30
Study 11503006 — intervention group
Group type: COMPARATOR
Intervention: Triazolam alone
Number of subjects: 30
Study 9403400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention service package
Number of subjects: 1800
Study 9403400 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1800
Study 8352177 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status (smokers)
Number of subjects: 0
Study 8352177 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking status (nonsmokers)
Number of subjects: 0
Study 8352177 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct location
Number of subjects: 0
Study 3306290 — intervention group
Group type: EXPERIMENTAL
Intervention: Org OD 14 (2.5 mg/day)
Number of subjects: 0
Study 29248604 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress ball intervention (group 2)
Number of subjects: 120
Study 29248604 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy intervention (group 3)
Number of subjects: 120
Study 29248604 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1)
Number of subjects: 120
Study 27491025 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus reduced-dose cyclosporine (EVR group)
Number of subjects: 24
Study 27491025 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil plus standard-dose cyclosporine (STD group)
Number of subjects: 24
Study 27491025 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EVR and STD)
Number of subjects: 24
Study 24631948 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (platinum-based, primarily single-agent carboplatin)
Number of subjects: 120
Study 24631948 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant chemotherapy
Number of subjects: 120
Study 24631948 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/paclitaxel
Number of subjects: 120
Study 22159017 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA-based test
Number of subjects: 12
Study 22159017 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO simplified grading system (TF)
Number of subjects: 12
Study 22159017 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA-based test
Number of subjects: 12
Study 20729740 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon and ribavirin treatment
Number of subjects: 145
Study 18716855 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological risk and resilience factors combined with knee X-rays
Number of subjects: 275
Study 18716855 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 275
Study 16648917 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rubs
Number of subjects: 54
Study 16648917 — intervention group
Group type: COMPARATOR
Intervention: Negative control (water)
Number of subjects: 54
Study 16648917 — intervention group
Group type: COMPARATOR
Intervention: Sodium dodecyl sulfate (SDS) control
Number of subjects: 54
Study 12674130 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-progestin hormone replacement therapy
Number of subjects: 16000
Study 12674130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16000
Study 11014413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen and caffeine
Number of subjects: 301
Study 11014413 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 301
Study 11014413 — intervention group
Group type: COMPARATOR
Intervention: Caffeine alone
Number of subjects: 301
Study 11014413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 8989060 — intervention group
Group type: EXPERIMENTAL
Intervention: Salm-1 (50 micrograms of salmeterol, single dose)
Number of subjects: 8
Study 8989060 — intervention group
Group type: EXPERIMENTAL
Intervention: Salm-2 (regular treatment with salmeterol for 1 week)
Number of subjects: 8
Study 8989060 — intervention group
Group type: COMPARATOR
Intervention: Plac-1 (single dose of placebo)
Number of subjects: 8
Study 8989060 — intervention group
Group type: COMPARATOR
Intervention: Plac-2 (regular treatment with placebo for 1 week)
Number of subjects: 8
Study 1455910 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms of vaccine
Number of subjects: 20
Study 1455910 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of vaccine
Number of subjects: 20
Study 1455910 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms of vaccine
Number of subjects: 20
Study 1455910 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 micrograms of vaccine
Number of subjects: 20
Study 1455910 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of vaccine
Number of subjects: 20
Study 6365236 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg tablet
Number of subjects: 100
Study 6365236 — intervention group
Group type: COMPARATOR
Intervention: Isoconazole 300 mg tablets (2 tablets)
Number of subjects: 100
Study 29847356 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Electrosurgery Skill Trainer (VEST)
Number of subjects: 20
Study 29847356 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 28830742 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (1.5G twice daily for 16 weeks)
Number of subjects: 67
Study 28830742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 26348920 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral Training Group (UG)
Number of subjects: 43
Study 26348920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Training Group (BG)
Number of subjects: 43
Study 26348920 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 43
Study 25039544 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) plus saline
Number of subjects: 107
Study 25039544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus saline
Number of subjects: 107
Study 25039544 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 107
Study 22709278 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary virtual patient module
Number of subjects: 226
Study 22709278 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to virtual patient module)
Number of subjects: 226
Study 20811340 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (cholinesterase inhibitor)
Number of subjects: 0
Study 20811340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17920357 — intervention group
Group type: EXPERIMENTAL
Intervention: High clopidogrel loading dose (>300 mg)
Number of subjects: 1567
Study 17920357 — intervention group
Group type: COMPARATOR
Intervention: Standard clopidogrel loading dose (300 mg)
Number of subjects: 1567
Study 12761725 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy
Number of subjects: 0
Study 12761725 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapies (artificial sphincter procedures and dynamic graciloplasty)
Number of subjects: 0
Study 12761725 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer, less invasive therapeutic approaches
Number of subjects: 0
Study 12761725 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of risk factors
Number of subjects: 0
Study 10761756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m2 day 1, etoposide 120 mg/m2 day 1‐3 (bolus therapy)
Number of subjects: 120
Study 10761756 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of carboplatin 100 mg/m2/week for six weeks (infusional therapy)
Number of subjects: 120
Study 8968699 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoenergetic 1000 kJ (240 kcal) portions of test foods
Number of subjects: 38
Study 8968699 — intervention group
Group type: EXPERIMENTAL
Intervention: Test foods producing a higher insulin response
Number of subjects: 38
Study 8968699 — intervention group
Group type: EXPERIMENTAL
Intervention: Total carbohydrate content of foods
Number of subjects: 38
Study 1598096 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (t-PA) (100 mg)
Number of subjects: 20768
Study 1598096 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (1.5 million units)
Number of subjects: 20768
Study 1598096 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 20768
Study 1598096 — intervention group
Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 20768
Study 6539187 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 10
Study 6539187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30854442 — intervention group
Group type: EXPERIMENTAL
Intervention: Belinostat (PXD‐101)
Number of subjects: 0
Study 28554878 — intervention group
Group type: EXPERIMENTAL
Intervention: AR glasses
Number of subjects: 20
Study 28554878 — intervention group
Group type: COMPARATOR
Intervention: PALS pocket reference cards
Number of subjects: 20
Study 25843412 — intervention group
Group type: EXPERIMENTAL
Intervention: Treprostinil 250µM via cathodal iontophoresis (40mC/cm²)
Number of subjects: 24
Study 25843412 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9%
Number of subjects: 24
Study 24640437 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% arginine and 1450 ppm F as sodium monofluorophosphate in a dicalcium phosphate dihydrate base
Number of subjects: 119
Study 24640437 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.0% arginine and 1450 ppm F as sodium monofluorophosphate in a calcium carbonate base
Number of subjects: 119
Study 24640437 — intervention group
Group type: COMPARATOR
Intervention: Commercially available fluoride dentifrice without arginine (1450 ppm F as sodium monofluorophosphate in a dical base)
Number of subjects: 119
Study 21238825 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 44
Study 21238825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 21238825 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomized arm (midazolam)
Number of subjects: 44
Study 21238825 — intervention group
Group type: COMPARATOR
Intervention: All groups (midazolam and placebo)
Number of subjects: 44
Study 19473596 — intervention group
Group type: COMPARATOR
Intervention: Deferiprone tablet (GPO‐L‐ONE, 500 mg, 3 tablets)
Number of subjects: 24
Study 17460145 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1 g twice daily
Number of subjects: 248
Study 17460145 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (75 to 100 mg/d)
Number of subjects: 248
Study 17273657 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral polymyxin (2.5 mg/kg in 4 daily doses for 7 days)
Number of subjects: 25
Study 17273657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17273657 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral polymyxin
Number of subjects: 25
Study 11763939 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral‐B CrossAction toothbrush
Number of subjects: 75
Study 11763939 — intervention group
Group type: COMPARATOR
Intervention: Comparison toothbrushes (seven other toothbrushes)
Number of subjects: 75
Study 8795324 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron alone (4 mg bolus and 0.13 mg.ml‐1 in the morphine solution)
Number of subjects: 60
Study 8795324 — intervention group
Group type: COMPARATOR
Intervention: Droperidol alone (1.25 mg bolus and 0.05 mg.ml‐1 in the morphine solution)
Number of subjects: 60
Study 8795324 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (ondansetron and droperidol)
Number of subjects: 60
Study 1352331 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate topically and acetazolamide 125 mg orally
Number of subjects: 39
Study 1352331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 39
Study 6507184 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg)
Number of subjects: 0
Study 6507184 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 31569780 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive non-surgical periodontal therapy (test group; n = 20)
Number of subjects: 40
Study 31569780 — intervention group
Group type: COMPARATOR
Intervention: Professional tooth cleaning (control group; n = 20)
Number of subjects: 40
Study 30059542 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacing of cue-approach training
Number of subjects: 0
Study 30059542 — intervention group
Group type: COMPARATOR
Intervention: Massing schedule of cue-approach training
Number of subjects: 0
Study 27053715 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (300 mg/d)
Number of subjects: 24
Study 27053715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 24767550 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) pulpotomy
Number of subjects: 62
Study 24767550 — intervention group
Group type: COMPARATOR
Intervention: Mineral trioxide aggregate (MTA) pulpotomy
Number of subjects: 62
Study 24767550 — intervention group
Group type: COMPARATOR
Intervention: Both PRF and MTA
Number of subjects: 62
Study 23428763 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of levobupivacaine
Number of subjects: 60
Study 23428763 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of levobupivacaine plus 8 mg of lornoxicam
Number of subjects: 60
Study 23428763 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of levobupivacaine plus 8 mg of lornoxicam and 8 mg of morphine
Number of subjects: 60
Study 20698715 — intervention group
Group type: EXPERIMENTAL
Intervention: Erigeron breviscapus (EBHM) extract, 2 tablets three times a day for 6 months
Number of subjects: 40
Study 20698715 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 2 tablets three times a day for 6 months
Number of subjects: 40
Study 18757091 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate ≥70 bpm
Number of subjects: 5438
Study 18757091 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate increase of 5 bpm
Number of subjects: 5438
Study 18757091 — intervention group
Group type: COMPARATOR
Intervention: Heart rate <70 bpm
Number of subjects: 5438
Study 15634721 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-wk GH replacement therapy (9.5 microg/kg.d)
Number of subjects: 10
Study 15634721 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline values or changes in erythrocyte SLC activity, adiponectin, leptin, and IGFBP-1
Number of subjects: 10
Study 12890208 — intervention group
Group type: EXPERIMENTAL
Intervention: TL01 phototherapy and topical calcipotriol cream (50 microg g(‐1))
Number of subjects: 50
Study 12890208 — intervention group
Group type: COMPARATOR
Intervention: TL01 phototherapy and topical emollient as placebo
Number of subjects: 50
Study 10383531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatin minimicrospheres
Number of subjects: 37